{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T14:16:18Z","timestamp":1769177778026,"version":"3.49.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:p>Chronically elevated low-density lipoprotein (LDL) has harmful effects on the vasculature including increased vasoconstriction and the formation of plaques which may rupture, causing coronary heart disease and stroke. In patients with familial hypercholesterolemia, adequate reduction of LDL is especially challenging. Although HMG-CoA reductase inhibitors (statins) are the mainstays for LDL lowering, other treatments such as proprotein convertase subtilisin\/kexin type 9 inhibitors, bempedoic acid, incliseran, lomitapide, and apheresis have been employed in an effort to achieve adequate LDL reduction in these patients. Despite these available therapies, many patients with familial hypercholesterolemia do not meet the LDL targets suggested in current guidelines. Evinacumab is a novel lipid-lowering therapy that exerts its LDL-lowering effect through inhibition of angiopoietin-like protein 3 (ANGPTL3). ANGPTL3 inhibits the breakdown of triglyceride-rich lipoproteins, such as very low-density lipoprotein and chylomicrons. By inhibiting ANGPTL3, evinacumab allows these lipoproteins to be degraded, ultimately leading to reductions in LDL, high-density lipoprotein, and triglycerides. Clinical trials have demonstrated evinacumab to be safe and effective in reducing LDL. However, data are lacking regarding its potential to reduce risk of atherosclerotic cardiovascular disease. Evinacumab is generally well tolerated with the primary adverse effects comprising infusion reactions, nasopharyngitis, influenza-like illness, dizziness, rhinorrhea, and nausea. While evinacumab is an interesting therapy, until it is proven to reduce cardiovascular events, its high cost leaves its anticipated role in therapy somewhat ambiguous. In the meantime, it may be a useful therapy for those with homozygous familial hypercholesterolemia.<\/jats:p>","DOI":"10.1097\/crd.0000000000000522","type":"journal-article","created":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T16:10:26Z","timestamp":1681834226000},"page":"180-185","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Evinacumab-dgnb (Evkeeza-REGN1500), A Novel Lipid-Lowering Therapy for Homozygous Familial Hypercholesterolemia"],"prefix":"10.1097","volume":"32","author":[{"given":"Raechel T.","family":"White","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice and Administrative sciences, College of Pharmacy, University of New Mexico Health Science Center, Albuquerque, NM"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kjersten H.","family":"Sankey","sequence":"additional","affiliation":[{"name":"University of New Mexico College of Pharmacy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James J.","family":"Nawarskas","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Administrative sciences, College of Pharmacy, University of New Mexico Health Science Center, Albuquerque, NM"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,4,18]]},"reference":[{"key":"R1-20250619","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"R2-20250619","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41569-018-0052-6","article-title":"The complex molecular genetics of familial hypercholesterolaemia.","volume":"16","author":"Berberich","year":"2019","journal-title":"Nat Rev Cardiol"},{"key":"R3-20250619","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society.","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur Heart J"},{"key":"R5-20250619","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS).","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"R6-20250619","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines.","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"R7-20250619","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jacl.2019.10.005","article-title":"Long-term effect of 2 intensive statin regimens on treatment and incidence of cardiovascular events in familial hypercholesterolemia: The SAFEHEART study.","volume":"13","author":"P\u00e9rez de","year":"2019","journal-title":"J Clin Lipidol"},{"key":"R8-20250619","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/MOL.0000000000000755","article-title":"Inhibition of angiopoietin-like 3 for the management of severe hypercholesterolemia.","volume":"32","author":"Mohamed","year":"2021","journal-title":"Curr Opin Lipidol"},{"key":"R9-20250619","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1194\/jlr.M300031-JLR200","article-title":"A decreased expression of angiopoietin-like 3 is protective against atherosclerosis in apoE-deficient mice.","volume":"44","author":"Ando","year":"2003","journal-title":"J Lipid Res"},{"key":"R12-20250619","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1358\/dot.2021.57.10.3317240","article-title":"Evinacumab to treat hypercholesterolemia.","volume":"57","author":"Engler","year":"2021","journal-title":"Drugs Today (Barc)"},{"key":"R13-20250619","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJMc1705994","article-title":"ANGPTL3 inhibition in homozygous familial hypercholesterolemia.","volume":"377","author":"Gaudet","year":"2017","journal-title":"N Engl J Med"},{"key":"R14-20250619","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1161\/ATVBAHA.120.315204","article-title":"ANGPTL3 inhibition with evinacumab results in faster clearance of IDL and LDL apoB in patients with homozygous familial hypercholesterolemia\u2014brief report.","volume":"41","author":"Reeskamp","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R15-20250619","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.atherosclerosis.2020.10.013","article-title":"A randomized study investigating the safety, tolerability, and pharmacokinetics of evinacumab, an ANGPTL3 inhibitor, in healthy Japanese and Caucasian subjects.","volume":"314","author":"Harada-Shiba","year":"2020","journal-title":"Atherosclerosis"},{"key":"R16-20250619","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1161\/CIRCULATIONAHA.118.039107","article-title":"Inhibition of angiopoietin-like protein 3 with a monoclonal antibody reduces triglycerides in hypertriglyceridemia.","volume":"140","author":"Ahmad","year":"2019","journal-title":"Circulation"},{"key":"R17-20250619","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa2031049","article-title":"Evinacumab in patients with refractory hypercholesterolemia.","volume":"383","author":"Rosenson","year":"2020","journal-title":"N Engl J Med"},{"key":"R18-20250619","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for homozygous familial hypercholesterolemia.","volume":"383","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"key":"R19-20250619","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/FJC.0000000000001073","article-title":"Efficacy and safety of evinacumab for the treatment of hypercholesterolemia: a meta-analysis.","volume":"78","author":"Jin","year":"2021","journal-title":"J Cardiovasc Pharmacol"},{"key":"R24-20250619","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.atherosclerosis.2012.02.016","article-title":"Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials.","volume":"223","author":"Morrone","year":"2012","journal-title":"Atherosclerosis"},{"key":"R25-20250619","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes.","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"R27-20250619","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease.","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"R28-20250619","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jacc.2020.05.027","article-title":"Efficacy and safety of alirocumab in adults with homozygous familial hypercholesterolemia.","volume":"76","author":"Blom","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"R29-20250619","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jacc.2019.12.020","article-title":"Long-term evolocumab in patients with familial hypercholesterolemia.","volume":"75","author":"Santos","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"R30-20250619","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1001\/jama.2019.16585","article-title":"Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR wisdom randomized clinical trial.","volume":"322","author":"Goldberg","year":"2019","journal-title":"JAMA"},{"key":"R31-20250619","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and efficacy of bempedoic acid to reduce LDL cholesterol.","volume":"380","author":"Ray","year":"2019","journal-title":"N Engl J Med"},{"key":"R32-20250619","doi-asserted-by":"crossref","first-page":"e011662","DOI":"10.1161\/JAHA.118.011662","article-title":"Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance.","volume":"8","author":"Laufs","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"R33-20250619","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.2147\/DDDT.S251865","article-title":"Bempedoic acid for heterozygous familial hypercholesterolemia: from bench to bedside.","volume":"15","author":"Agarwala","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"R34-20250619","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the treatment of heterozygous familial hypercholesterolemia.","volume":"382","author":"Raal","year":"2020","journal-title":"N Engl J Med"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000522","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T16:02:31Z","timestamp":1750348951000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,18]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000522","relation":{},"ISSN":["1061-5377"],"issn-type":[{"value":"1061-5377","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4,18]]}}}